Case report

A case of placental site trophoblastic tumor complicating nephrotic syndrome in which hysteroscopic biopsy did not yield a definitive diagnosis

Wataru Sato*, Yasuko Miura, Hiromitsu Shirasawa, Yukiyo Kumazawa, Jin Kumagai, Yukihiro Terada

Department of Obstetrics and Gynecology, Akita University Graduate School of Medicine, Akita, Japan

Abstract

Placental site trophoblastic tumor (PSTT) is the rarest subtype of gestational trophoblastic neoplasm. We present a case of PSTT complicating nephrotic syndrome. A 32-year-old woman experienced irregular menstrual bleeding and lower extremity edema 18 months after delivery. She was diagnosed with nephrotic syndrome and exaggerated placental site based on the hysteroscopic biopsy results. During follow-up, transvaginal color Doppler ultrasound showed an enlarged uterus filled with a hypervascular mass. Positron emission tomography—computed tomography showed diffuse accumulation in the entire uterus. The patient was diagnosed with PSTT only after total hysterectomy. Postoperatively, serum b-hCG decreased to within the normal range and her nephrotic syndrome resolved. She has remained without evidence of recurrence for 15 months. It is difficult to diagnose PSTT definitively. Most patients with PSTT are of reproductive age, therefore, to maintain fecundity, therapy development is expected.

Introduction

Placental site trophoblastic tumor (PSTT) is the rarest subtype of gestational trophoblastic neoplasm (GTN), which is characterized by intermediate trophoblasts at the site of placental implantation.1 In 1976, Kurman et al described this entity for the first time using the name trophoblastic pseudotumor.2 In 1981, Scully and Young coined the term PSTT to describe the malignant potential of this tumor.3 PSTT is a rare subtype of GTNs, with almost 300 cases reported worldwide.4 GTNs are rarely associated with nephrotic syndrome, and only a few cases have been documented.5 It is difficult to diagnose PSTT definitively. Most cases are often diagnosed definitively after total hysterectomy. Most patients with PSTT are of reproductive age, therefore, to maintain fecundity, therapy development is expected.

Case report

A 32-year-old woman, gravida 1 para 1, gave birth to a healthy full-term baby through normal vaginal delivery. For 17 months after delivery, the patient had amenorrhea, and urinary human chorionic gonadotropin (hCG) was positive. Because irregular bleeding was detected, the patient consulted a medical practitioner. The diagnosis was chemical abortion, because laboratory investigations showed that urinary hCG was positive. At 18 months after delivery, she was admitted to hospital with irregular menstrual bleeding and sudden onset of lower extremity edema. Laboratory investigations showed severe proteinuria, urinary hCG positivity, low serum protein (5.0 g/dL), and low serum albumin (2.7 g/dL). A renal biopsy showed thrombotic microangiopathy. She was diagnosed with nephrotic syndrome, and she was treated with steroid. Computed tomography (CT) for etiological determination revealed an enlarged uterus, and she was referred to our department. Transvaginal ultrasound and magnetic resonance imaging (MRI) showed an enlarged uterus, but the tumor was not found clearly in the uterus (Figure 1B). The serum b-hCG level was 289 mIU/mL. During hysteroscopy, villus-like pathological changes were observed in the
uterine cavity, so hysteroscopic biopsy was performed to make a definitive diagnosis. Microscopically, there were increased numbers of intermediate trophoblasts, and tumor cells were arranged in sheets and cords throughout the smooth muscle fibers of the myometrium, without invading blood vessel walls in the myometrium. Immunohistochemically, the tumor cells were positive for hPL and hCG, and the Ki-67 labeling index was ~20%. She was diagnosed with an exaggerated placental site (EPS), because the Ki-67 labeling index was high, but a neoplastic lesion was not detected clinically and mitotic figures were not found by histopathology. In addition, the entire uterus showed uptake on 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)-CT (Figure 1D). Methotrexate (MTX) therapy was commenced after diagnosis of EPS. MTX therapy was given as an intramuscular injection of 20 mg/day for 5 days. Serum β-hCG values decreased from 292 mIU/mL to 88 mIU/mL after MTX therapy. On PET-CT, the accumulation image accepted it, but there was a clear decrease in maximum standardized uptake value. (D) Before MTX treatment; (E) after MTX treatment. CT = computed tomography; MRI = magnetic resonance imaging; MTX = methotrexate; PET = positron emission tomography.
gestational trophoblastic disease, we performed histological diagnosis under hysteroscopy, but this did not lead to a definitive diagnosis. Ultimately, we had to perform total hysterectomy to make a definitive diagnosis.

Discussion

Both PSTT and EPS are diseases in which intermediate trophoblasts multiply excessively at an implantation site. The distinction is based on whether they represent multiplying tumor cells, and on the presence or absence of failure of the myometrium and the vasculature caused by the neoplasm. Several studies have stated that initial imaging, such as CT or MRI, is necessary to confirm a neoplastic lesion. Furthermore, the diagnosis is confirmed by immunohistochemical testing of endometrial tissue from hysteroscopy and curettage for markers such as hPL, hCG, and the Ki-67 labeling index. However, in our patient, a neoplastic lesion was not present on CT and MRI, which led to a diagnosis of EPS, not PSTT, based on the results of the hysteroscopic biopsy. Furthermore, there are several reports that PET-CT is useful for monitoring for recurrence. However, there are no reports describing the use of PET-CT for diagnosis of PSTT. PET-CT showed diffuse accumulation in the entire uterus, and not focal accumulation expected of a nodular neoplastic lesion. It is suggested that we cannot exclude PSTT because there is not a neoplastic lesion.

In addition, GTNs are rarely associated with nephrotic syndrome; only a few cases have been documented. In those cases, nephrotic syndrome completely resolved after hysterectomy. Our case followed a similar course. The association is not clear, but when there is acute renal disease and continuously high levels of hCG, it is necessary to consider trophoblastic disease, including PSTT, in the differential diagnosis.

While GTNs are generally sensitive to chemotherapy, PSTT is chemoresistant. Therefore, treatment for PSTT is primarily surgical; particularly if the disease is contained in the uterus. When the disease has progressed outside of the uterus, prognosis is poor due to the chemoresistance of PSTT. Therefore, total hysterectomy is necessary in order to diagnose PSTT correctly, and diagnosis at an early stage is important. In a review by Gillespie et al, patients with disease confined to the uterus who were treated surgically without chemotherapy remained disease-free with follow-up ranging from 3 months to 10 years. Similarly, Hassadia et al found that patients with Stage I disease treated only with surgery remained recurrence-free with follow-up ranging from 3 months to 10 years. Our patient had disease confined to the uterus, so the treatment was completed only by total hysterectomy, based on a previous report.

In conclusion, it is difficult to diagnose PSTT definitively, because the morbidity and clinical characteristics of PSTT have not been clarified completely. Definitive diagnosis of PSTT requires pathological diagnosis by total hysterectomy. However, most patients with PSTT are of reproductive age, therefore, it is a problem that we cannot maintain fecundity by total hysterectomy. Improvements in the diagnostic evaluation and therapeutic strategy of PSTT, for example, molecular targeting therapy does not depend on surgery, are expected in the future.

References

1. Hyman DM, Bakios I, Gualtiere G, et al. Placental site trophoblastic tumor: analysis of presentation, treatment, and outcome. Gynecol Oncol. 2013;129:58–62.
2. Kurman RJ, Scully RE, Norris HJ. Trophoblastic pseudo tumor of the uterus: an exaggerated from of “syncytiotendometriitis” stimulating a malignant tumor. Cancer. 1976;38:1214–1226.
3. Scully RE, Young RH. Trophoblastic pseudo tumor: a reappraisal. Am J Surg Pathol. 1981;5:75–76.
4. Luiza John W, Taylor Sarah E, Gao Faye F, Edwards Robert P. Placental site trophoblastic tumor: immunohistochemistry algorithm key to diagnosis and review of literature. Gynecol Oncol Res. 2014;7:13–15.
5. Batra Vineeta, Kalra Om Prakash, Mathur Prashant, Kavita, Dev Geeta. Membranous glomerulopathy associated with placental site trophoblastic tumor: a case report. Nephrol Dial Transplant. 2007;22:1766–1768.
6. Chua AAA, Huang KG, Wu KY. The application of hysteroscopy in gestational trophoblastic disease. *Gynecol Minim Invasive Ther*. 2016;5:30–32.

7. Sardo ADS, Calagna G, Di Carlo C. Tips and tricks in office hysteroscopy. *Gynecol Minim Invasive Ther*. 2015;4:3–7.

8. Schmid P, Nagai Y, Agarwal R, et al. Prognostic markers and long-term outcome of placental-site trophoblastic tumors: a retrospective observational study. *Lancet*. 2009;374:1186–1190.

9. Gillespie AM, Liyim D, Goepel JR, Coleman RE, Hancock BW. Placental site trophoblastic tumor: a rare but potentially curable cancer. *Br J Cancer*. 2000;82:1186–1190.

10. Hassadia A, Gillespie A, Tidy J, et al. Placental site trophoblastic tumor: clinical features and management. *Gynecol Oncol*. 2005;99:603–607.